Last edition
News about "Clinical trial Phase I"
Avacta Group doses first patient in AVA6103 trial, advances targeted cancer therapy platform
Phase I FOCUS-01 study to evaluate novel peptide-drug conjugate across four solid tumours following Euro 10 million fundraise and collaboration with Tempus AI.
Clinical Trial Phase I | 11/04/2026 | By News Bureau | 175
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members